Horsholm, Denmark, February 14, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its Chief Scientific Officer, Dr. Willem Adriaan (“Wian”) de Jongh, is appointed the honorary position of affiliated associate professor at the Technical University of Denmark (“DTU”). The position […]
On August 23 2016 ExpreS2ion Biotechnologies ApS, Horsholm, Denmark (”ExpreS2ion”) and the Francis Crick Institute, London, United Kingdom, announce that they have amended their Research License Agreement to extend the research based on ExpreS2ion’s proprietary ExpreS2 expression system for another year.
The article “Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system” was recently published in Scientific Reports. Abstract The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has recently emerged as a leading candidate antigen against the blood-stage human malaria parasite. However […]
ExpreS2ion Biotechnologies’ scientists contributed to the research for the article by Thrane et al, ”Bacterial superglue enables easy development of efficient virus-like particle based vaccines”, which is published in the Journal of Nanobiotechnology, on 27th April, 2016. The article documents an exciting VLP vaccine platform enabling the binding of complex […]
The talk titled “Development of Drosophilia S2 based sub-unit antigen vaccine production processes” will be held on Day 1 (Monday, March 21st) under the session titled “Challenges and Solutions in Vaccine Discovery: Novel Target Expression Systems” More information about the conference at http://www.ntnv.org/
The meeting features the most exciting and challenging discussions on the industry’s most difficult applications including viral gene vectors and vaccines, adeno-associated virus (AAV), and other products derived with insect cell technology. Follow the link for more information: http://www.isbiotech.org/springtravel.html
Edited by Robert W. Sauerwein and Thomas L. Richie Access the journal issue here: http://www.sciencedirect.com/science/journal/0264410X/33/52 Articles citing the use of ExpreS2: Recent advances in recombinant protein-based malaria vaccines. Draper et al.
BioEurope 2015 November 2–4, 2015, Munich, Germany http://www.ebdgroup.com/bioeurope/media/about_conf.php Is your project being slowed down by protein manufacturing challenges? Try ExpreS2, a virus-free insect cell expression system, easy to scale and regulatory friendly. Meet us at BioEurope for an introductory discussion. We are sponsoring the 16th World Vaccine Congress Europe 2015 […]
The execution with Boston Children’s Hospital, located in Boston, Massachusetts, USA, of a non-exclusive research license agreement to use ExpreS2ion’s proprietary recombinant protein expression platform ExpreS2 for Boston Children’s academic research. Boston Children’s is the pediatric teaching affiliate of Harvard Medical School. Read the PR
March 2015 A vaccine against placental malaria made with ExpreS2ion® Biotechnologies protein expression technology, ExpreS2, is ready to start human tests in Germany and Benin. Placental malaria vaccine to start human tests in Germany and Benin February 2015 ExpreS2ion® Biotechnologies licenses the ExpreS2 system to the Gene Center in Munich, […]